| Dr Ryan K Riggs, MD | |
|
11762 S State St Ste 110, Draper, UT 84020 | |
| (801) 495-3539 | |
| (801) 996-8785 |
| Full Name | Dr Ryan K Riggs |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 26 Years |
| Location | 11762 S State St Ste 110, Draper, Utah |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1669415881 | NPI | - | NPPES |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Actijoint, Llc | 8022279520 | 2 |
| Integrated Joint Specialists Llc | 7517148554 | 12 |
| Integrated Joint Specialists Llc | 7517148554 | 12 |
News Archive
The Associated Press reports that a California state law created a state agency to oversee implementation of the health law and gave it authority to keep what it spent on contractors a secret.
The National Cancer Moonshot initiative needs to move beyond genomics to target the proteins that are driving cancer, according to an Inova Health System and George Mason University collaborative paper published Thursday in the American Association for Cancer Research.
A team led by scientists at The Scripps Research Institute has developed a potential new treatment for heart attacks. The therapy inhibits fluid leakage from cardiac blood vessels following a heart attack and thereby significantly prevents long-term heart damage and improves survival.
Velos, Inc., the trusted leader in clinical trial management systems for large academic medical centers and research institutions, today announced an initiative to provide solutions for customers in the areas of risk management and compliance monitoring in research, transplant medicine, and biospecimen management.
Vanda Pharmaceuticals Inc. today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for tasimelteon, a circadian regulator.
› Verified 9 days ago
| Entity Name | Emergency Physicians Integrated Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578598199 PECOS PAC ID: 4284548116 Enrollment ID: O20031115000013 |
News Archive
The Associated Press reports that a California state law created a state agency to oversee implementation of the health law and gave it authority to keep what it spent on contractors a secret.
The National Cancer Moonshot initiative needs to move beyond genomics to target the proteins that are driving cancer, according to an Inova Health System and George Mason University collaborative paper published Thursday in the American Association for Cancer Research.
A team led by scientists at The Scripps Research Institute has developed a potential new treatment for heart attacks. The therapy inhibits fluid leakage from cardiac blood vessels following a heart attack and thereby significantly prevents long-term heart damage and improves survival.
Velos, Inc., the trusted leader in clinical trial management systems for large academic medical centers and research institutions, today announced an initiative to provide solutions for customers in the areas of risk management and compliance monitoring in research, transplant medicine, and biospecimen management.
Vanda Pharmaceuticals Inc. today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for tasimelteon, a circadian regulator.
› Verified 9 days ago
| Entity Name | Actijoint, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376810176 PECOS PAC ID: 8022279520 Enrollment ID: O20120410000450 |
News Archive
The Associated Press reports that a California state law created a state agency to oversee implementation of the health law and gave it authority to keep what it spent on contractors a secret.
The National Cancer Moonshot initiative needs to move beyond genomics to target the proteins that are driving cancer, according to an Inova Health System and George Mason University collaborative paper published Thursday in the American Association for Cancer Research.
A team led by scientists at The Scripps Research Institute has developed a potential new treatment for heart attacks. The therapy inhibits fluid leakage from cardiac blood vessels following a heart attack and thereby significantly prevents long-term heart damage and improves survival.
Velos, Inc., the trusted leader in clinical trial management systems for large academic medical centers and research institutions, today announced an initiative to provide solutions for customers in the areas of risk management and compliance monitoring in research, transplant medicine, and biospecimen management.
Vanda Pharmaceuticals Inc. today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for tasimelteon, a circadian regulator.
› Verified 9 days ago
| Entity Name | Signify Health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689158487 PECOS PAC ID: 3274895263 Enrollment ID: O20210225002062 |
News Archive
The Associated Press reports that a California state law created a state agency to oversee implementation of the health law and gave it authority to keep what it spent on contractors a secret.
The National Cancer Moonshot initiative needs to move beyond genomics to target the proteins that are driving cancer, according to an Inova Health System and George Mason University collaborative paper published Thursday in the American Association for Cancer Research.
A team led by scientists at The Scripps Research Institute has developed a potential new treatment for heart attacks. The therapy inhibits fluid leakage from cardiac blood vessels following a heart attack and thereby significantly prevents long-term heart damage and improves survival.
Velos, Inc., the trusted leader in clinical trial management systems for large academic medical centers and research institutions, today announced an initiative to provide solutions for customers in the areas of risk management and compliance monitoring in research, transplant medicine, and biospecimen management.
Vanda Pharmaceuticals Inc. today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for tasimelteon, a circadian regulator.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ryan K Riggs, MD 6243 W 10220 N, Highland, UT 84003-3436 Ph: (801) 651-4876 | Dr Ryan K Riggs, MD 11762 S State St Ste 110, Draper, UT 84020 Ph: (801) 495-3539 |
News Archive
The Associated Press reports that a California state law created a state agency to oversee implementation of the health law and gave it authority to keep what it spent on contractors a secret.
The National Cancer Moonshot initiative needs to move beyond genomics to target the proteins that are driving cancer, according to an Inova Health System and George Mason University collaborative paper published Thursday in the American Association for Cancer Research.
A team led by scientists at The Scripps Research Institute has developed a potential new treatment for heart attacks. The therapy inhibits fluid leakage from cardiac blood vessels following a heart attack and thereby significantly prevents long-term heart damage and improves survival.
Velos, Inc., the trusted leader in clinical trial management systems for large academic medical centers and research institutions, today announced an initiative to provide solutions for customers in the areas of risk management and compliance monitoring in research, transplant medicine, and biospecimen management.
Vanda Pharmaceuticals Inc. today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for tasimelteon, a circadian regulator.
› Verified 9 days ago
Todd William Furness, D.O. General Practice Medicare: Accepting Medicare Assignments Practice Location: 74 E Kimballs Ln Ste 260, Draper, UT 84020 Phone: 801-545-8480 Fax: 801-253-1602 |